Considerations in evaluating new antianginal drugs.
Diseases that cause symptoms incompletely relieved by available modes of treatment stimulate search for new therapies. Chronic disease processes, in which interventions are palliative rather than curative provide a particular challenge in determining the value of therapeutic intervention. Management of patients with angina pectoris is an example of this challenge.
D000787:Angina Pectoris / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008013:Lidoflazine / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D012107:Research Design; D014700:Verapamil / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D008013:Lidoflazine